Volition's Nu.Q® discover biomarkers to be utilized in human clinical study sponsored by leading pharmaceutical company for the first time (PRNewswire)
"VolitionRx...today announces that it has signed an agreement with a leading pharmaceutical company to utilize Volition's Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b study. The Nu.Q® Discover program provides drug developers and scientists with a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to market ready...Following a successful pilot study, two of Volition's Nu.Q® Discover assays were selected for use in this study. It is expected to be completed over a 12-18 month period, generating significant revenue for Volition for this study alone, with further projects being discussed."